All News

The FDA’s Vaccines and Related Biological Products Advisory Committee voted in favor of granting BNT162b2, the COVID-19 vaccine developed by Pfizer and BioNTech, emergency use authorization.

Prior to receiving behavioral interventions, more than half of participating young survivors of breast cancer were considered clinically depressed. That number dropped to 30% after participants received mindfulness meditation and survivorship education classes.

Women with higher diet adherence scores after diagnosis had a 33% lower risk for all-cause mortality and a 17% lower risk for mortality related to breast cancer compared with women with lower diet adherence scores.

This week on the “CURE® Talks Cancer” podcast, we spoke with renowned street artist James Cochran about one of his art projects that was commissioned to symbolize the creativity and commitment of those who work tirelessly to eradicate cancer.

Of note, the results indicated that patients with breast cancer who were younger than 60 and of Black or other race were more likely to experience under-recognized symptoms by their physician.

Recently presented data demonstrated that a combination of oral paclitaxel and Encequidar elicited promising results in patients with radiation-associated breast angiosarcoma.

In addition to having greater efficacy, the combination of oral paclitaxel and encequidar demonstrated lower rates of chemotherapy-induced peripheral neuropathy in patients with metastatic breast cancer compared to intravenous paclitaxel.

Younger age, breast cancer diagnosis, Medicaid insurance and treatment type were associated with an increased risk for women becoming new chronic users of opioids or sedatives/hypnotics following mastectomy with reconstructive surgery.

The combination of ublituximab and umbralisib, two novel compounds, was able to safely prolong progression-free survival with low rates of toxicities in patients with chronic lymphocytic leukemia compared with standard of care chemoimmunotherapy regardless of prior treatment.

The early study of the investigational CAR-T cell therapy lisocabtagene maraleucel shows how patients with relapsed/refractory CLL/SLL may have a viable new treatment option.

This data, according to a resident physician at Brigham and Women’s Hospital, highlights the need for systematic mental health screening and management for individuals with blood cancers.

Do you have a favorite recipe that has helped you through cancer treatments and recovery? CURE® invites you to participate in its Second Annual Recipe Swap by sharing your favorite meals, side dishes and snacks.

Patients with aggressive lymphomas experienced sharp increases in quality of life from time of diagnosis until one year later and continued to see improvements for almost a decade.

Most of the potential years of life lost, a measure of the impact of cancer-related deaths especially in younger patients, were attributed to cancers such as colon, lung and breast.

The benefit observed in patients with Waldenstrom’s macroglobulinemia treated with Imbruvica (ibrutinib) plus Rituxan (rituximab), compared with placebo and Rituxan, focused on survival and response to the treatment, both of which occurred despite prior treatment and genotypes.

Dr. Knight presents findings that suggest financial intervention can improve mortality rate in patients with hematologic malignancy at the 2020 ASH Meeting.

A patient with cancer discusses how one oncology nurse helped guide his cancer treatment to a better place.

Compared with patients assigned bendamustine with Rituxan, those assigned Venclexta with Rituxan maintained an overall survival benefit, with a five-year OS estimate of 82.1% for the Venclexta with Rituxan group vs. 62.2% for the bendamustine with Rituxan group.

Data suggest that patients with CLL/SLL who achieve confirmed undetectable minimal residual disease following 12 cycles of Imbruvica combined with Venclexta could possibly discontinue and reasonably remain off treatment.

An analysis of the phase 2 study IMbark shows how imetelstat can offer patients with high-risk myelofibrosis multiple clinical benefits, setting the stage for an expanded phase 3 trial.

The phase 3 trial found that this treatment improves progression-free survival (PFS) during 18.7 months of follow-up, although patients treated with Venclexta (venetoclax) a had increased mortality rates compared with those treated with placebo.

Emily Whitehead was the first child to receive chimeric antigen receptor (CAR)-T cell therapy. Eight years later, she and her parents discuss her ongoing remission from acute lymphoblastic leukemia.

From a recently published study showing preliminary connections between elevated levels of stress-related hormones and cancer recurrence, to a Texas mayor receiving a diagnosis of cancer and COVID-19, here’s what’s happening in the cancer landscape this week.

Evolving standards of care in newly diagnosed multiple myeloma (MM) have given patients a wider variety of possibilities but can also be disconcerting. In a presentation during CURE®’s Educated Patient® Multiple Myeloma Summit, Dr. Clifton Mo, of Dana-Farber Cancer Institute, explores the treatment landscape and breaks down what these different options can offer patients.

Chimeric antigen receptor (CAR)-T cell therapy is becoming more widely available, with two drugs approved to treat specific blood cancers and more being investigated in clinical trials across cancer types. Here’s what patients need to know if they’re considering treatment with one of these novel immunotherapies.

The reduced incidence in developing advanced cancer in patients at least 50 years and older was more prominent in those with normal weight vs. overweight or obesity.

An artificial intelligence-based algorithm within the electronic medical record provided real-time and accurate predictions of the short-term mortality rate of patients with cancer, outperforming all other prognostic incidences commonly used.

Safety and efficacy observed in this real-world study for patients with non-Hodgkin lymphoma similarly reflect findings from previous pivotal trials.